Benefits of Omega-3 For Your Heart
Heart Health
Clinical evidence supports the use of EPA and DHA from fish and fish
oils for cardiovascular health, with little or no evidence supporting
the use of ALA or DPA-related products. Studies in top medical journals
on omega-3 and heart health were based on the consumption of EPA and DHA
from fish and fish oils, not flax, krill, seal or whale oil.
By incorporating See Yourself Well™
EPA and DHA into a treatment plan, within 4-6 weeks a patient will:
- reduce the risk of developing heart disease by
32%
- reduce the risk of death from heart attack by 70%
- lower blood TG levels by 32%
- reduce plaque build-up in arteries by 75%
- correct irregular heartbeat
- reduce the risk of stroke by 30%
- reduce resting heart rate by 5 beats per minute
Dosage:*
In order to capture all of the risk factors indicated above, the
patient should consume 3 grams of combined See Yourself Well™ EPA and
DHA omega-3 per day as follows:
-
. 5 of the 1,000mg capsules,
OR
-
.10 of the 500mg capsules,
OR
- 1 teaspoon of the liquid oil
* Dosage recommendations given are intended to cover all risk
reductions listed and are based on 600mg or 60% EPAlDHA concentrate of 1
gram of fish oil.
* The American Heart Association recommends 900 mg EPAlDHA for heart
health maintenance and the FDA recommends 3,000 mg EPAlDHA for blood TG
lowering.
Warning
- Not All Omega 3s Are The Same:
Unless the Omega-3, which comes from. fish oil, is molecularly
distilled, it contains high levels of hazardous contaminants such as
mercury. See Yourself WellTM Professional Grade Omega-3 is ultra-refined
and concentrated while providing premium quality and optimum health
benefit. All See Yourself WellTM products are tested for compliance with
the standards set by the Council for Responsible Nutrition and the World
Health Organization and receive a 5-Star rating from the International
Fish Oil Standards Program.
( Available for viewing at
www.ifosprogram.com )
References
Berbert et ai, J. Of nutr., London State Univ. Brazil, 2005. Lopez-Garica
et. AI., J. Nutr., 134: 1806-1811, 2004. Merchant et aI., AJCN., 82-
668-674, 2005. Lu et aI., Am. J. Epid., 161:948-959,2005. Miljanoiv et
aI., AJCN. 82:887-893,2005. Mickleborough et al. Am J. Respir. Crit.
Care Med., 2003. Peat et aI., J. Allergy Clin Immunology, 114(4):807813,
2004. Proc Natl Acad Sci USA. 2005 May 17;102(20):7133-8. Epub 2005 May
9. A. Richardson and P. Montgomery, Pediatrics, 115: 1360-1366, 2005.
Yuen et aI., Epilepsy and Behaviour, 7:253-258, 2005. Whalley, et aI.,
AJCN, 80: 1650-1657, 2004. Hibbeln, NIH, 2005. Br J Cancer. 2003 Nov
3;89(9):1686-92. Augustsson et aI., Cancer Epid., Biomarkers, and Prev.,
12: 64-67, 2003. Norat et aI., J. Natl. Cancer Inst., 97:906-16, 2005.
Simon et ai, AJE, 1995, also AHA Statement, 2000. A.M. Gotto, Circ.
97:1027, 1998. Billman, GE, Proc. Natl. Acad. Sci. 1994. LeMaitre et aI.,
AJCN, 77:319, 2003. He et aI., Stroke, 35: 1358-1542, 2004. Holub BJ.,
CMAJ, 166:609-615, 2002. |
|
